26,176 reports of this reaction
20.6% of all ONABOTULINUMTOXINA reports
#1 most reported adverse reaction
DRUG INEFFECTIVE is the #1 most commonly reported adverse reaction for ONABOTULINUMTOXINA, manufactured by Allergan, Inc.. There are 26,176 FDA adverse event reports linking ONABOTULINUMTOXINA to DRUG INEFFECTIVE. This represents approximately 20.6% of all 126,795 adverse event reports for this drug.
ONABOTULINUMTOXINA has an overall safety score of 78 out of 100. Patients taking ONABOTULINUMTOXINA who experience drug ineffective should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INEFFECTIVE is a frequently reported adverse event for ONABOTULINUMTOXINA, accounting for a significant proportion of all reports.
In addition to drug ineffective, the following adverse reactions have been reported for ONABOTULINUMTOXINA:
The following drugs have also been linked to drug ineffective in FDA adverse event reports:
DRUG INEFFECTIVE has been reported as an adverse event in 26,176 FDA reports for ONABOTULINUMTOXINA. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INEFFECTIVE accounts for approximately 20.6% of all adverse event reports for ONABOTULINUMTOXINA, making it one of the most commonly reported side effect.
If you experience drug ineffective while taking ONABOTULINUMTOXINA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.